Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in <scp>A</scp>sian patients with type 2 diabetes mellitus

Abstract

In this population, EQW and EBID showed efficacious glucose and weight control; safety and tolerability were consistent with observations in non-Asian patients. This trial was registered with ClinicalTrials.gov (no. NCT00917267).